Participation of GABAA receptors in the modulation of experimental anxiety by tachykinin agonists and antagonists in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 5, 2002, Pages 861-869

  Ribeiro, Rafaela L ^a   De Lima, Thereza C M ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Anxiety; Benzodiazepines; GABA; Plus maze; Tachykinins

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; DIAZEPAM; FLUMAZENIL; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NEUROKININ 2 RECEPTOR AGONIST; NEUROKININ 3 RECEPTOR ANTAGONIST; NEUROKININ A; NEUROKININ[4-10][7 TRYPTOPHAN BETA 8 ALANINE]; PENTETRAZOLE; SAREDUTANT; SENKTIDE; SUBSTANCE P; TACHYKININ RECEPTOR AGONIST; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; TACHYKININ; TACHYKININ RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; LOCOMOTION; MAZE TEST; MOTOR COORDINATION; MOUSE; NONHUMAN; ANIMAL; ANXIETY; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY;

ANIMALS; ANXIETY; DIAZEPAM; FEMALE; MICE; RECEPTORS, GABA-A; RECEPTORS, TACHYKININ; TACHYKININS;

EID: 0036591303     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00331-1     Document Type: Article

References (66)

1. Act 1992. Guidelines To Use Animals in Research. Brazilian Society of Neuroscience and Behavior, SBNEC. FeSBE Caxambu, MG, Brazil.
2. Aguiar M.S., Brandão M.L. Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behavior of the rats in the plus-maze test. Physiol. Behav. 60:1996;1183-1186.
3. Andreattini R., Leite J.R. Effect of valepotriates on the behavior of rats in the elevated plus-maze during diazepam withdrawal. Eur. J. Pharmacol. 260(2-3):1994;233-235.
4. Aosaki T., Kawaguchi Y. Actions of substance P on rat neostriatal neurons in vitro. J. Neurosci. 16:1996;5141-5153.
5. 1 antagonist SR 140333 in the mouse black and white box model. Proceedings of the 25th Annual Meeting of the Society for Neuroscience, San Diego. 1995;1696 Society for Neurosciences, Washington, DC, USA.
6. Brandão M.L., Anseloni V.Z., Pandóssio J.E., De Araújo J.E., Castilho V.M. Neurochemical mechanisms of the defensive behavior in the dorsal midbrain. Neurosci. Biobehav. Rev. 23:1999;863-875.
7. 3-receptors in guinea-pig ileum and taenia caeci: in vitro characterization by their first non-peptide antagonist, SR 142801. Life Sci. 57:1995;361-366.
8. Culman J., Unger T. Central tachykinins: mediators of defense and stress reactions. Can. J. Physiol. Pharmacol. 73(1):1995;885-891.
9. Dawson G.R., Crawford S.R., Collington N., Iverson S.D., Tricklebank M.D. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus-maze are confounded by increases in locomotor activity. Psychopharmacology. 118:1995;316-323.
10. De Araújo J.E., Silva R.C.B., Huston J.P., Brandão M.L. Anxiogenic effects of substance P and its 7-11 C-terminal, but not the 1-7 N terminal, injected into the dorsal periaqueductal gray. Peptides. 20:1999;1437-1444.
11. 3) in the central nervous system of the rat. J. Comp. Neurol. 364:1996;290-310.
12. Drapeau G., Rouissi N., Nantel F., Rhaleb N.E., Tousignant C., Regoli D. Antagonists for the tachykinin NK-3 receptor evaluated in selective receptor systems. Regul. Pept. 31:1990;125-135.
13. Dunham N.W., Miya T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc. 46:1957;208-210.
14. 2) receptor. Life Sci. 50:1992;101-106.
15. File S.E. Anxiolytic action of a tachykinin 1 receptor antagonist in the social interaction test. Pharmacol., Biochem. Behav. 58:1997;747-752.
16. 1 receptor antagonist, FK 888. Br. J. Pharmacol. 107:1992;785-789.
17. Gavioli E.C., Canteras N.S., De Lima T.C.M. Anxiogenic-like effect induced by substance P injected into the lateral septal nucleus. NeuroReport. 10:1999;3399-3403.
18. Gavioli E.C., Canteras N.S., De Lima T.C.M. The role of lateral septal NK1 receptors in mediating anxiogenic effects induced by intracerebroventricular injection of substance P. Behav. Brain Res. 2001;. submitted for publication.
19. Geyer M.A., Russo P.V., Masten V.L. Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol., Biochem. Behav. 25:1986;277-288.
20. Giardina G.A.M., Raveglia L.F. Tachykinin-3 receptor antagonists. Exp. Opin. Ther. Pat. 7:1997;307-323.
21. Giardina G.A.M., Sarau H.M., Farina C., Medhurst A.D., Grugni M., Raveglia L.F., Schmidt D.B., Rigolio R., Luttmann M., Vecchietti V., Hay D.W.P. Discovery of a novel class of selective non-peptide antagonists for the human tachykinin-3 receptor: 1. Identification of the 4-quinolinecarboxamide framework. J. Med. Chem. 40:1997;1794-1807.
22. Giusti P., Arban R. Physiological and pharmacological basis for the diverse properties of benzodiazepines and their congeners. Pharmacol. Res. 27:1993;201-215.
23. Graeff F.G. Ansiolíticos. Graeff F.G. Drogas psicotrópicas e seu modo de ação. 1989;61-83 Ed. Pedagógica e Universitária Ltda, São Paulo.
24. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. 12:1957;12-15.
25. Hasenöhrl R.U., Jentjens O., De Souza Silva M.A., Tomaz C., Huston J.P. Anxiolytic-like action of tachykinin substance P administered systemically or into the nucleus basalis magnocellularis region. Eur. J. Pharmacol. 354:1998;123-133.
26. Helke C.J., Krause J.E., Mantyh P.W., Couture R., Bannon M.J. Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. FASEB J. 4:1990;1606-1615.
27. Hendry S., Jones E.G., De Filipe J., Schmechel D., Brandon C., Emson P.C. Co-localization of GABA and neuropeptides In the cerebral cortex. Proc. Natl. Acad. Sci. USA. 81:1984;6526-6530.
28. Horwell D.C. The 'peptoid' approach to the design of non-peptide, small molecule agonists and antagonists of neuropeptides. TIBTECH. 13:1995;132-134.
29. Iversen L.L., McNight A.T., Foster A.C., Young S.C., Williams B.J. Pharmacology of the tachykinin system. Schwartz T.W., Hilsted L.M., Rehfeld J.F. Neuropeptides and Their Receptors. 1990;363-372 Munksgaard, Copenhagen.
30. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt-Knowles E., Hale J.J., Mills S.G., Maccoss M., Swain C.J., Harrison T., Hill R.G., Hefti F., Scolnick E.M., Cascieri M.A., Chicchi G.G., Sadowski S., Williams A.R., Hewson L., Smith D., Carlson E.J., Hargreaves R.J., Rupniak N.M.J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1998;1640-1645.
31. Lader M.H. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur. Neuropsychopharmacol. 9(Suppl. 6):1999;S399-S405.
32. Laursen S.E., Belknap J.P. Intracerebro-ventricular injections in mice. Some methodological refinements. J. Pharmacol. Methods. 16:1986;155-157.
33. Lee C., Rodgers R.J. Effects of benzodiazepine receptor antagonist, flumazenil, on antinociceptive and behavioural responses to the elevated plus-maze in mice. Neuropharmacology. 30:1991;1263-1267.
34. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
35. Lister R.G. Ethologically-based animal models of anxiety disorders. Pharmacol. Ther. 46:1990;321-340.
36. Lüddens H., Korpi E.R., Seeburg P.H.S. GABAa/benzodiazepine receptor heterogeneity: neurophysiological implications. Neuropharmacology. 34:1995;245-254.
37. Maggio J.E. Tachykinins. Annu. Rev. Neurosci. 11:1988;13-28.
38. Mauborgne A., Javoy-Agid F., Legrand J.C., Agid Y., Cessetin F. Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains. Brain Res. 268:1983;167-170.
39. Mussap C.J., Geraghty D.P., Burcher E. Tachykinin receptors: a radioligand binding perspective. J. Neurochem. 60:1993;1987-2009.
40. Nakanishi S. Mammalian tachykinin receptors. Annu. Rev. Neurosci. 14:1991;123-136.
41. Nogueira E., Rosa G.J., Vassilieff V.S. Involvement of GABA(A)-benzodiazepine receptor in the anxiolytic effect induced by hexanic fraction of Rubus brasiliensis. J. Ethnopharmacol. 61:1998;119-126.
42. Otsuka M., Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73:1993;229-308.
43. Patacchini R., Maggi C.A. Tachykinin receptors and receptor subtypes. Arch. Int. Phamacodyn. Ther. 329(1):1995;161-184.
44. Pernow B. Substance P. Pharmacol. Rev. 35:1983;85-141.
45. 3H] γ -aminobutyric acid release. Neurosci. Lett. 284:2000;89-92.
46. Pritchard M.C., Boden P. Tachykinin NK3 receptors: biology and development of selective peptide and non-peptide ligands. Drugs. 20:1995;1163-1173.
47. Regoli D., Drapeau G., Dion S., D'Orléans-Juste P. Receptors for substance P and related tachykinins. Pharmacology. 38:1989;1-15.
48. Regoli D., Boudon A., Fauchére J-L. Receptors and antagonists for substance P related peptides. Pharmacol. Rev. 46:1994;551-599.
49. 3 receptor modulation of experimental anxiety in mice. Neurosci. Lett. 258:1998;1-4.
50. 3 receptor involvement in anxiety. Neuropeptides. 33(2):1999;181-188.
51. Rodgers R.J., Cao B.J., Dalvi A., Holmes A. Animal models of anxiety: an ethological perspective. Braz. J. Med. Biol. Res. 30:1997;289-304.
52. 1) receptors attenuates neonatal vocalization in guinea-pigs and mice. Neuropharmacology. 39:2000;1413-1421.
53. 1 receptor in the brain: pharmacology and putative functions. Eur. J. Pharmacol. 375(1-3):1999;51-60.
54. Seabrook G.R., Bowery B.J., Hill R.G. Pharmacology of tachykinin receptors on neurons in the ventral tegmental area of rat brain slices. Eur. J. Pharmacol. 273:1995;113-119.
55. Shughrue P.J., Lane M.V.L., Merchenthaler I. In situ hybridization analysis of the distribution of neurokinin-3 mRNA in the rat central nervous system. J. Comp. Neurol. 372:1996;395-414.
56. - ion channels modulated by multiple drug-binding sites. Trends Pharmacol. Sci. 13:1992;446-450.
57. 3 receptors. Neuropeptides. 27:1994;333-341.
58. 2 receptor antagonists in the mouse light-dark box. Eur. J. Pharmacol. 250:1993;R11-R12.
59. 2 receptor antagonist, release supressed behaviors in a novel aversive environment. Br. J. Pharmacol. 112:1994;49.
60. Teixeira R.M., Santos A.R.S., Ribeiro S.J., Calixto J.B., Rae G.A., De Lima T.C.M. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur. J. Pharmacol. 311:1996;7-14.
61. 3 receptors in the human prefrontal and visual cortex. Neurosci. Lett. 283:2000;185-188.
62. 2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology. 121:1995;186-191.
63. Wise S.P. Co-localization of GABA and neuropeptides in the cerebral cortex. Trends Neurosci. 3:1985;92-95.
64. Wormser V., Laufer R., Mart Y., Chorev M., Gilon C., Selinger Z. Highly selective agonists for substance P receptor subtypes. EMBO J. 5:1986;2805-2808.
65. 9, Met(O2)11]substance P. Neuroscience. 94(2):1999;663-673.
66. Zernig G., Troger J., Saria A. Different behavioral profiles of the non-peptide substance P (NK1) receptor antagonists CP-96, 345 and RP 67580 in Swiss albino mice in the black-and-white box. Neurosci. Lett. 151:1993;64-66.